GROWTHFORGE · BEACON · SOURCE-BACKED SIGNAL
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
NCT07039422 is on the Cheap-to-Truth Radar because its public ClinicalTrials.gov record contains a recent development signal worth inspecting. This page is not a recommendation or diligence conclusion.
Priority to inspect76/100
StatusWITHDRAWN
PhasePHASE2
Lead sponsorNovartis Pharmaceuticals
Last update2026-10-15
Public-record facts
| Intervention | Ianalumab (BIOLOGICAL) |
|---|---|
| Condition | Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia |
| Enrollment | 0 |
| Why stopped | The study was discontinued due to evolving scientific \& feasibility considerations that could adversely affect recruitment, thereby reducing the likelihood of generating a sufficiently robust dataset to support reliable efficacy \& safety conclusions. |
| Results posted | No / not indicated |
Why Beacon surfaced it
- The record is withdrawn and was updated 2026-10-15.
- It is an interventional PHASE2 study with a named biological intervention.
- The lead sponsor is classified as industry.
- The record states a reason for stopping, creating a concrete diligence question.
What Cheap-to-Truth would verify next
- Was the stopping reason scientific, operational, financial, strategic, or mixed?
- What human safety and efficacy evidence actually exists beyond the registry summary?
- Who controls the relevant rights, and are they practically obtainable?
- Is there an indication and endpoint where a smaller experiment could answer the key decision?
- Would the resulting data be usable by the regulator that matters?
Source: ClinicalTrials.gov NCT07039422. Registry information is sponsor/investigator submitted; verify primary evidence before making development decisions.